EULAR 2025

Interfering on the long run: less difficult-to-treat pts. after 1st line anti-TNF in early RA?

Preventing, delaying or early sufficient treatment of RA?

What about malignancies with JAKi treatment?

Benefit of MTX underpinned in newly diagnosed PMR!

Cardiovascular impact of GLP-1 receptor agonists in patients with AS

IL-17A/IL-17F-inhibiting nanobody as a new molecule in PsA

TYK2-Inhibitors a new oral treatment option?

Real world data of Adalimumab vs Ixekizumab in PsA

Cardiovascular impact of GLP-1 receptor agonists in patients with AS

Cancer reactivation in axSpA patients treated with TNF-blocker

New bispecific antibodies against axSpA?

Effect of TNF inhibitors on the risk of cancer recurrence in AS

Sex-specific response on biologics

Subjective or objective endpoints - is there a preference?

Connection between pain and disease activity

The IL-17 story continues!

Impact of biologics on cardiovascular outcome in AS

Impact of GLP-1 receptor agonists on cardiovascular events in AS

Zusammenhang von Schmerz und Krankheitsaktivität

Neue bispezifische Antikörper gegen axSpA?

Impatto degli agonisti del recettore GLP-1 sugli eventi cardiovascolari nella spondilite anchilosante (AS)

Effetti degli inibitori del TNF sul rischio di recidiva di cancro nella spondilite anchilosante (AS)

Krebs-Reaktivierung bei mit TNF-Blockern behandelten axSpA-Patienten

Die IL-17-Story geht weiter!

Impatto dei farmaci biologici sugli esiti cardiovascolari nella spondilite anchilosante (AS)

Subjektive oder objektive Endpunkte - gibt es eine Präferenz?

Geschlechtsspezifisches Ansprechen auf Biologika

Real world data of Adalimumab vs Ixekizumab in PsA

TYK2-Inhibitors a new oral treatment option?

IL-17A/IL-17F-inhibiting nanobody as a new molecule in PsA

Sexual health in patients with PsA

TYK2: convenient, safe and effective!

Difficult-to-treat patients in active PsA

Sonelokimab - again IL-17 inhibition or new IL-17 inhibition?

TYK2 inhibitors in PsA

Hit hard & early or tight control - two ways to reach the goal

MTX+LEF strategy vs MTX alone in PsA

Sonelokimab, a novel IL-17A- and IL-17F-inhibiting nanobody, demonstrates strong efficacy

Definitions and prevalence of difficult-to-treat PsA

IL-23 stops radiographic progress

High prevalence of PsA in PsO patients without musculoskeletal symptoms

Sonelokimab, a novel IL-17A- and IL-17F-inhibiting nanobody, demonstrates strong efficacy

TYK2: bequem, sicher und auch wirksam!

Hohe Prävalenz von PsA bei PsO-Patienten ohne muskoskelettale Symptome

TYK2-Inhibitoren bei PsA

Hit Hard & Early oder Tight Control - zwei Wege zum Ziel

Difficult-to-treat patients in active PsA

IL-23 stoppt radiografischen Progress

Santé sexuelle au cours du rhumatisme psoriasique

Sonelokimab - schon wieder IL-17-Inhibition oder neue IL-17-Inhibition?

Definición y prevalencia de la APs difícil de tratar

Stratégie MTX+LEF vs MTX seul dans le rhumatisme psoriasique

Interfering on the long run: less difficult-to-treat pts. after 1st line anti-TNF in early RA?

Preventing, delaying or early sufficient treatment of RA?

What about malignancies with JAKi treatment?

New treatment options in RA

Cancer risk under biologic therapy in RA

ILD in rheumatoid arthritis

Safety of JAKies in RA

Cancer incidence in RA from the JAK-POT study

Abatacept in individuals at risk of delevoping RA

Prophylactic therapy with abatacept in patients at risk of RA

Risque de cancer sous biomédicament dans la PR

Abatacept en individuos en riesgo de desarrollar AR

Cancer incidence in RA from the JAK-POT study

Prophylaktische Therapie mit Abatacept bei Patienten mit RA-Risiko

Benefit of MTX underpinned in newly diagnosed PMR!

Benefit of MTX underpinned in newly diagnosed PMR

Benefit von MTX bei neu diagnostizierter PMR untermauert

Cardiovascular outcomes of treat-to-target urate-lowering treatment in gout

Desenlaces cardiovasculares del tratamiento por objetivos de la uricemia en gota

Cancer mortality in inflammatory joint diseases

New therapeutic approach for refractory myositis

Combination therapies in immune mediated inflammatory diseases

Cost-effectiveness of therapeutic drug monitoring

Patient history matters: real-world data of infliximab biosimilar

Cost-effectiveness of therapeutic drug monitoring

Neuer Therapieansatz für refrakträre Myositis

Kombinationstherapien bei immunvermittelten entzündlichen Erkrankungen

Die Patientengeschichte zählt: Infliximab-Biosimilar Real-World Daten

Cancer mortality in inflammatory joint diseases